| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 10/29/2013 | US8568707 Light emitting microorganisms and cells for diagnosis and therapy of tumors |
| 10/29/2013 | CA2612362C Cdna construct of salmonidae alphavirus |
| 10/29/2013 | CA2589471C Antibodies and peptide antigens for producing antibodies having a selective binding specificity to bioactive intact parathyroid hormone (pth) 1-84 |
| 10/29/2013 | CA2589204C Recombinant bcg strains with enhanced ability to escape the endosome |
| 10/29/2013 | CA2546619C Il-23 and its receptor; related reagents and methods |
| 10/29/2013 | CA2535515C Cd20-binding polypeptide compositions |
| 10/29/2013 | CA2511512C Immunogenic compositions containing phospholipid |
| 10/29/2013 | CA2509136C Human il-1 beta antagonists |
| 10/29/2013 | CA2488968C Peptides for regulation of urokinase (upa) and tissue type (tpa) plasminogen activator and method of optimizing therapeutic efficacy |
| 10/29/2013 | CA2481952C Immunological methods and compositions for the treatment of alzheimer's disease |
| 10/29/2013 | CA2477406C Dna vaccine against proliferating endothelial cells and methods of use thereof |
| 10/29/2013 | CA2466128C Antibodies to cd40 |
| 10/29/2013 | CA2458001C Regulation of immune responses by manipulation of intermediary metabolite levels |
| 10/29/2013 | CA2453100C Novel human hepatoma lines, methods for obtaining same and uses thereof |
| 10/29/2013 | CA2446408C Recombinant mhc molecules useful for manipulation of antigen-specific t-cells |
| 10/29/2013 | CA2435672C Polypeptides capable of binding to cd64 and comprising one or more heterologous t cell epitopes, and their uses |
| 10/29/2013 | CA2396992C Hybrid cells |
| 10/27/2013 | CA2776119A1 P97 protein and uses thereof as vaccine adjuvant |
| 10/24/2013 | WO2013158913A1 Treating cancer |
| 10/24/2013 | WO2013158841A1 Peptide mimotopes to oxidation specific epitopes |
| 10/24/2013 | WO2013158821A2 Methods of treating ankylosing spondylitis using il-17 antagonists |
| 10/24/2013 | WO2013158818A2 Vaccines and methods to treat lyme disease in dogs |
| 10/24/2013 | WO2013158782A2 Methods and compositions for treating cardiac arrhythmias |
| 10/24/2013 | WO2013158748A1 Human antibodies and specific binding sequences thereof for use in stroke and ischemia or ischemic conditions |
| 10/24/2013 | WO2013158673A1 Mesoporous silica compositions for modulating immune responses |
| 10/24/2013 | WO2013158611A1 Methods and compositions for the treatment of glioblastomas |
| 10/24/2013 | WO2013158516A1 Methods for treating or preventing influenza virus infection by administering a serine protease inhibitor |
| 10/24/2013 | WO2013158485A1 Menainv and cancer invasion and metastasis |
| 10/24/2013 | WO2013158276A1 Antibody binding microbial heparin binding motif to retard or prevent microbial biofilm formation on implanted medical devices |
| 10/24/2013 | WO2013158274A1 ANTI-MIGE ANTIBODIES THAT BIND TO THE JUNCTION BETWEEN CH4 AND CεMX DOMAINS |
| 10/24/2013 | WO2013158217A1 Engineered antibody for inhibition of fibrosis |
| 10/24/2013 | WO2013157105A1 Mucin 5ac specific human antibody and use thereof |
| 10/24/2013 | WO2013157102A1 Mucin 5ac specific human antibody and use thereof |
| 10/24/2013 | WO2013156976A1 Prevention and treatment of non-viral infections in individuals treated with immunosuppressants |
| 10/24/2013 | WO2013156949A1 Rodent plasmodium parasites as platforms for a whole-organism malaria vaccine |
| 10/24/2013 | WO2013156771A1 Anti-atherogenic peptides |
| 10/24/2013 | WO2013156587A1 Biomass hetero-colloidal systems, production and uses thereof |
| 10/24/2013 | WO2013156534A1 Cross-reactive staphylococcus aureus antibody |
| 10/24/2013 | WO2013156473A1 Combination therapy of anti-mif antibodies and chemotherapeutics |
| 10/24/2013 | WO2013156472A1 Combination therapy of anti-mif antibodies and glucocorticoids |
| 10/24/2013 | WO2013156467A1 Plant profilin polypeptides for use in non-specific allergy immunotherapy |
| 10/24/2013 | WO2013156148A1 THE IgM AND IgE HEAVY CHAIN DOMAIN 2 AS COVALENTLY LINKED HOMODIMERIZATION MODULES FOR THE GENERATION OF FUSION PROTEINS WITH DUAL SPECIFICITY |
| 10/24/2013 | WO2013156054A1 The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity |
| 10/24/2013 | WO2013155890A1 Antigen composition, preparation method and use thereof, and tumor vaccine |
| 10/24/2013 | WO2013111012A3 Methods and compositions for therapeutic agents |
| 10/24/2013 | WO2013085550A3 V1v2 immunogens |
| 10/24/2013 | WO2012104820A9 Compositions for canine respiratory disease complex |
| 10/24/2013 | WO2012054748A3 Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the pi3k-akt mtor pathway |
| 10/24/2013 | US20130281876 Therapies for improving pulmonary function |
| 10/24/2013 | US20130280322 Vaccine |
| 10/24/2013 | US20130280302 Pharmaceutical product comprising mite allergen extract(s) and a method for the manufacture thereof |
| 10/24/2013 | US20130280301 Non-Natural Amino Acid Replication-Dependent Microorganisms and Vaccines |
| 10/24/2013 | US20130280300 Polypeptides and Immunizing Compositions Containing Gram Positive Polypeptides and Methods of Use |
| 10/24/2013 | US20130280299 Viral vectors and their use in therapeutic methods |
| 10/24/2013 | US20130280298 Immunogenic Affinity-Conjugated Antigen Systems Based on Papaya Mosaic Virus and Uses Thereof |
| 10/24/2013 | US20130280296 Dna vaccine against multitypes of avian influenza viruses and influenza virus-like particles comprising adjuvant-fused m2 protein |
| 10/24/2013 | US20130280295 Aluminum compounds for use in therapeutics and vaccines |
| 10/24/2013 | US20130280294 Bovine viral diarrhea virus type 1b vaccine compositions and methods |
| 10/24/2013 | US20130280293 Combination heptavalent vaccine |
| 10/24/2013 | US20130280290 Nucleic Acid and Amino Acid Sequences, and Vaccine for the Control of Ectoparasite Infestations in Fish |
| 10/24/2013 | US20130280289 Mycobacterium antigenic composition |
| 10/24/2013 | US20130280288 Peptides protective against s. pneumoniae and compositions, methods and uses relating thereto |
| 10/24/2013 | US20130280287 Recombinant mycobacterium as vaccine for use in humans |
| 10/24/2013 | US20130280283 Combination of vaccination and inhibition of mhc class i restricted antigen presentation |
| 10/24/2013 | US20130280278 Anti-vegfr-3 antibody compositions |
| 10/24/2013 | US20130280277 Notch1 receptor binding agents and methods of use thereof |
| 10/24/2013 | US20130280276 Antibody targeting osteoclast-related protein siglec-15 |
| 10/24/2013 | US20130280272 Sustained release drug delivery systems comprising a water soluble therapeutic agent and a release modifier |
| 10/24/2013 | US20130280271 Inhibiting the integration of retrovirus dna into host cell dna by inhibiting integrase reaching dimer formation |
| 10/24/2013 | US20130280270 Methods of treating lung disease and other inflammatory diseases |
| 10/24/2013 | US20130280267 Purified antibody composition |
| 10/24/2013 | US20130280265 Synergistic anti-tumor efficacy using alloantigen combination immunotherapy |
| 10/24/2013 | US20130280264 Total and Phosphorylated IL-1 Receptor-Associated Kinase-1 and IL-1 Receptor-Associated Kinase-4 as a Biomarker for Cancer Progression and Chemotherapy Resistance |
| 10/24/2013 | US20130280258 Prognostic, diagnostic, and cancer therapeutic uses of fanci and fanci modulating agents |
| 10/24/2013 | US20130280254 Macrophage-synthesized ccl3 promotes breast cancer metastasis |
| 10/24/2013 | US20130280253 Il-1 binding proteins |
| 10/24/2013 | US20130280252 Method for selecting patient to be given drug for treating septicemia |
| 10/24/2013 | US20130280251 Stabilized Angiopoietin-2 Antibodies And Uses Thereof |
| 10/24/2013 | US20130280250 Dock-and-Lock (DNL) Constructs for Human Immunodeficiency Virus (HIV) Therapy |
| 10/24/2013 | US20130280248 Method of stabilizing antibody and stabilized solution-type antibody preparation |
| 10/24/2013 | US20130280247 Regulators of mmp-9 and uses thereof |
| 10/24/2013 | US20130280243 COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH A mTOR INHIBITOR |
| 10/24/2013 | US20130280242 Method of plscr inhibition for cancer therapy |
| 10/24/2013 | US20130280241 15-pgdh in colon cancer |
| 10/24/2013 | US20130280210 Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase |
| 10/24/2013 | US20130280209 Method for treating type 1 diabetes |
| 10/24/2013 | US20130280171 Method to optimize the treatment of patients with biological drugs |
| 10/24/2013 | US20130280167 Human antibodies and diagnostic and therapeutic uses thereof for the treatment of neurological disease |
| 10/24/2013 | US20130280163 Antibodies and molecules derived therefrom that bind to STEAP-1 proteins |
| 10/23/2013 | EP2653478A1 A novel antigen associated with the neovasculature of tumour metastases |
| 10/23/2013 | EP2652506A2 The use anti-cxcl16 and anti-cxcr6 antibodies for the treatment or detecting cancer |
| 10/23/2013 | EP2652498A2 Diagnosis and treatments relating to th2 inhibition |
| 10/23/2013 | EP2652496A1 Vaccine antigens that direct immunity to conserved epitopes |
| 10/23/2013 | EP2651978A1 Use of an antibody directed against a membrane protein |
| 10/23/2013 | EP2651975A1 Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof |
| 10/23/2013 | EP2651443A2 Anti-ccl25 and anti-ccr9 antibodies for the prevention and treatment of cancer and cancer cell migration |
| 10/23/2013 | EP2651442A2 Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer |
| 10/23/2013 | EP2651441A1 Anti-cd277 antibodies and uses thereof |
| 10/23/2013 | EP2651440A1 Cd89 activation in therapy |
| 10/23/2013 | EP2651439A2 Compositions and methods for the treatment or prevention of human adenovirus-36 infection |